6 November 2023, London – Qinecsa Solutions, specialists in technology-led end-to-end pharmacovigilance solutions, today announced the appointment of Arthur Shih as General Counsel. With over
Empowering leaders in small pharma and biotech with responsibility for drug safety We are thrilled to announce the launch of the Qinecsa PV Insights Network,
We are thrilled to be heading back to Boston to attend the World Drug Safety Congress US, which brings together 1000+ top leaders and stakeholders in
Our team is delighted to once again be attending the World Drug Safety Congress Europe, which brings together 1500+ key thought leaders to explore key
Author: Humaira Qureshi, President of Qinecsa Solutions The pharmacovigilance industry is in an unprecedented era of change. PV teams are experiencing year-on-year increases in case
Join Qinecsa at 32nd Pharmacovigilance 2023 to discuss the latest developments in pharmacovigilance, drug safety & risk management.Our President, Humaira Qureshi, will present ‘Fit for
A biotech had successfully completed Phase I clinical trials and was rapidly progressing into Phase II. Serious adverse event (SAE) volume was expected to significantly
A small pharma client with limited budget had several clinical compounds in Phase I and II, and one globally approved commercial product. They required robust
A small biotech with a healthy development pipeline had no internal pharmacovigilance expertise. They required a compliant drug safety framework to support safety data collection,
Dr Andrew Rut recently presented at the PV Legal Forum in Chicago on the importance of collecting and analyzing holistic safety data in order to
2 Leman Street,
London, E1W 9US
United Kingdom
Company number: 13916274
